|
|
||||||||
1 Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), C/ Darwin 3, Campus UAM, 28049 Madrid, Spain
2 Servicio de Microbiologia, Hospital Son Dureta, C/ Andrea Doria 55, 07014 Palma de Mallorca, Spain
Correspondence
Jesús Blázquez
blazquez{at}cnb.csic.es
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Interestingly, the isolation of P. aeruginosa strains producing a brown pigment from CF and COPD patients is not an infrequent event: in one study about 5 % of patients presented pyomelanogenic isolates (A. Oliver, unpublished results). Thus, the rationale was that these pyomelanin-hyperproducer strains could have an adaptive advantage in chronic infections (the pyomelanin itself being the cause of this advantage, or simply an unrelated epiphenomenon).
Several micro-organisms have been reported to produce pyomelanins (Yabuuchi & Ohyama, 1972
), including P. aeruginosa (Nosanchuk & Casadevall, 2003
; Ernst et al., 2003
). Vibrio cholerae melanin-producing mutants have been shown to be more virulent than the non-melanogenic isogenic strain (Ivins & Holmes, 1980
, 1981
; Ruzafa et al., 1995
), and the production of a melanin-like pigment may protect Burkholderia cepacia from host free-radicals, and thus may be considered a virulence factor (Zughaier et al., 1999
).
In the current research, we first determined that the molecular basis of pyomelanin hyperproduction in P. aeruginosa is the inactivation of the hmgA gene. Subsequently, we verified by genetic complementation that the hyperproduction of the dark-brown pigment in two CF pyomelanogenic clinical isolates was due to the inactivation of the hmgA gene. We also studied the effect of hmgA disruption on adaptation to chronic infections in murine lung infection models. Finally, the possible protective role of hmgA disruption and/or pyomelanin production against hydrogen peroxide and antibiotics was studied in vitro.
| METHODS |
|---|
|
|
|---|
Construction and screening of the insertional library.
Transposon insertions in the PAO1 chromosome were generated by following the protocol of Jacobs et al. (2003
). Briefly, E. coli strain SM10pir(pIT2), containing the transposon ISlacZ/hah, was mated with P. aeruginosa PAO1. Mutagenized cells were selected by plating on LB agar containing tetracycline (60 µg ml–1) to select insertions and chloramphenicol (10 µg ml–1) for counterselection against the E. coli donor strain. After incubation for 2 days at 30 °C, about 18 000 tetracycline-resistant colonies were picked and inoculated into 96-well plates, each well containing 200 µl freezing medium (LB broth plus 6 % glycerol) supplemented with tetracycline. Plates were incubated for 48 h at 37 °C, frozen and stored at –80 °C. Mutants producing a dark-brown pigment after incubation were isolated. Transposon insertion locations were determined by PCR and sequencing, as described by Jacobs et al. (2003)
.
Characterization of natural pyomelanogenic strains.
Two pyomelanogenic P. aeruginosa clinical isolates, recovered from the sputum samples of two different patients, were obtained from the collection of the Microbiology Department of the Son Dureta Hospital. Plasmids pBBR1-HmgA and pBBR1MCS-3 were transferred from E. coli S17-1 to the corresponding strains of P. aeruginosa. PCR amplification of the hmgA genes was performed using the primers described above.
Murine model of acute respiratory infection.
The murine model of acute lung infection was established by following previously described protocols (Mena et al., 2007
). Female C57BL/6 J mice, 20–25 g in weight (Harlan Interfauna Ibérica), were used. Before inoculation, the mice were anaesthetized by intraperitoneal injection of ketamine (100 mg kg–1; Pfizer) and xylazine (10 mg kg–1; Sigma-Aldrich). A vertical midline neck incision was then performed to expose the trachea of the mice, and 20 µl of 2x saline-washed culture, containing approx. 1x106 exponentially growing cells of PA14, the PA14 hmgA : : MAR2xT7 mutant, or a 1 : 1 mixture of both strains, was transtracheally inoculated. Mouse survival was monitored daily over a 7 day period in groups of 16 mice (from two independent experiments) for each of the strains. In the competition experiments, a group of eight mice inoculated with the 1 : 1 mixture was sacrificed 48 h after inoculation; the lungs were aseptically extracted and homogenized in 2 ml 0.9 % saline solution using an IKA Ultra-Turrax T-25 disperser. Serial 10-fold dilutions were plated in duplicate on Müller–Hinton agar (MHA). PA14 and the PA14 hmgA : : MAR2xT7 mutant colonies were differentiated by their green or brown pigment respectively, and the competition index (CI) was then calculated as the mutant/wild-type ratio. In order to rule out the possibility of loss of the phenotype during in vivo growth, a representative number (>10) of randomly selected colonies from each of the competition experiments were streaked on MHA with 20 µg gentamicin ml–1 (MHA-Gm), to verify the presence of the resistance marker of the PA14 hmgA : : MAR2xT7 mutant. All animal experiments were approved by the Animal Ethics Committees of the University of the Balearic Islands.
Murine model of chronic lung infection.
The murine model of chronic lung infection using P. aeruginosa-laden agarose beads was established by following previously described protocols (Macia et al., 2006
; Mulcahy et al., 2008
). Briefly, for the preparation of the agarose beads, P. aeruginosa strains were grown to late-exponential phase, washed and mixed at a 1 : 10 ratio with 2 % agarose in PBS (pH 7.4). The mixture was added to heavy mineral oil equilibrated at 55 °C, stirred for 6 min at room temperature and cooled for 10 min. The resulting agarose beads were washed with 0.5 and 0.25 % deoxycholic acid (sodium salt) in PBS once and then three times with PBS alone. Serial 1/10 dilutions of homogenized bead slurry aliquots were plated on MHA for a quantification of the bacterial content. Female C57BL/6 J mice, 20–25 g in weight (Harlan Ibérica), were used. The animals were specific pathogen free, and sterile water and food were provided ad libitum. Before inoculation, the mice were anaesthetized by intraperitoneal injection of ketamine (100 mg kg–1) and xylazine (10 mg kg–1). A vertical midline neck incision was then made to expose each mouse's trachea, and 20 µl of the bead preparation containing approximately 1x104 agarose-embedded cells was transtracheally inoculated. Mouse survival was monitored daily over a 7 day period in groups of 42 mice (from two independent experiments) for each of the strains. At 7 days post-infection animals were sacrificed. Lungs were aseptically extracted and homogenized in 2 ml 0.9 % saline solution using an Ultra-Turrax T-25 disperser. Serial 10-fold dilutions were plated in duplicate on MHA to calculate the c.f.u. An additional group of eight mice per strain was sacrificed 24 h after inoculation. Lungs were extracted, homogenized and plated, as described above. The statistical significance of the data was analysed by using Fischer's exact test, Student's t test, or the Mann–Whitney U-test, as appropriate. A P-value of <0.05 was considered significant.
Effect of hmgA inactivation and pyomelanin on peroxide resistance.
Five independent exponential-phase cultures of the wild-type, the hmgA variant and the complemented mutant grown in LB medium to OD600 0.5 were incubated at room temperature in the presence of 25 mM or 50 mM hydrogen peroxide (H2O2) for 15, 30, 45 and 60 min. Viable-cell counts were determined before and after treatment in both treated and untreated strains. The protective effect against peroxide of the supernatant from the pyomelanogenic strain was tested on the wild-type non-producer strain. PA14 cells obtained from 48 h cultures in LB were washed and resuspended in the sterilized (by filtration) supernatant from the PA14 hmgA : : MAR2xT7 pyomelanogenic mutant grown previously for 48 h in LB broth. As a control, identical experiments were performed using the supernatant obtained from the wild-type PA14 strain in the same conditions. The data were analysed using two-tailed unpaired t tests. P-values of 0.05 were considered statistically significant.
Effect of pyomelanin-containing medium on antibiotic resistance.
The minimal inhibitory concentrations (MICs) for ciprofloxacin, tobramycin, imipenen and ceftazidime were determined for the hmgA mutant and wild-type strain PA14. Approximately 103 cells from overnight cultures were inoculated into tubes containing 10 ml LB broth and incubated at 37 °C with vigorous shaking until the mid-exponential phase of growth (approx. 108 cells ml–1) was reached. Then 2x104 to 4x104 cells from these cultures were inoculated into each microdilution well of a microwell plate (1x105 to 2x105 c.f.u. ml–1) and incubated for 24 h. The MIC was defined as the lowest concentration of antibiotic at which no growth could be observed. The same experiment was repeated with the wild-type strain PA14 resuspended in the pyomelanin-containing supernatant from a 48 h culture of the mutant hmgA : : MAR2xT7.
| RESULTS AND DISCUSSION |
|---|
|
|
|---|
As indicated below, for further studies we decided to use the more virulent strain PA14 and its pyomelanin hyperproducer PA14 hmgA : : MAR2xT7 derivative (Liberati et al., 2006
) instead of PAO1. Fig. 1(A)
shows the phenotype of pyomelanin hyperproduction of PA14 hmgA : : MAR2xT7 in comparison to that of the wild-type PA14. To verify that the inactivation of the hmgA gene was the only cause of pyomelanin hyperproduction, we performed a complementation study. Hyperproduction was abolished when plasmid pBBR1-HmgA, harbouring the wild-type hmgA gene, was introduced into the PA14 hmgA : : MAR2xT7 mutant strain (Fig. 1B
). Similarly, the introduction of plasmid pBBR1-HmgA into the hmgA-deficient strain PAO1 hmgA : : ISlacZ/hah completely abolished the production of the pyomelanin pigment (data not shown).
|
|
Characterization of the molecular basis of pyomelanin hyperproduction in clinical isolates of P. aeruginosa
The results presented raised the following question: is hmgA inactivation the molecular basis for pyomelanin production in clinical isolates? To answer this, isolates from a series of CF patients were analysed for the production of the dark pigment. Two pyomelanin-hyperproducing P. aeruginosa clinical isolates, recovered from the sputum samples of two CF patients, were isolated and studied. The plasmid pBBR1-HmgA, harbouring the wild-type hmgA gene from the wild-type PA14 strain, was introduced into the two pyomelanogenic isolates and transconjugants were obtained in the two strains. The introduction of the wild-type hmgA gene completely abolished the pigment production in these strains. PCR amplification of the hmgA gene and its promoter region, using primers hmgAF1 and hmgAR1, rendered a positive result (a band of the expected size) in one of the strains only, suggesting that this strain has a minor modification in the hmgA gene. The PCR-amplified hmgA gene was sequenced to verify whether a mutation was present. Although some polymorphisms were found, none of them produced amino acid changes in the deduced protein, suggesting that mutations in other regions, such as transcriptional regulators, may be responsible for the observed phenotype. No PCR band was obtained in the other strain. As for the second strain, the use of hmgA internal primers and PCR controls demonstrated that the hmgA gene is absent in this strain and that the PCR was not inhibited in this case (data not shown). Therefore, these results strongly suggest that in both cases the lack of homogentisate 1,2-dioxygenase is responsible for the pyomelanogenic phenotype.
Mortality in the murine acute lung infection model
Pyomelanogenic strains appear to be more commonly found among clinical strains isolated from chronic infections such as CF and COPD (A. Oliver, unpublished). Thus, once it was determined that the lack of hmgA activity is responsible for pyomelanin hyperproduction in both laboratory mutants and clinical isolates, we decided to study whether hmgA inactivation confers an adaptive advantage in chronic infections. During the final steps of the characterization of the gene responsible for pyomelanin hyperproduction in our insertional library of PAO1, the construction of an ordered and nonredundant library of P. aeruginosa strain PA14 transposon insertion mutants was published by Liberati et al. (2006)
. We thought that since PA14 is a more virulent strain (Choi et al., 2002
), it would probably be more appropriate than PAO1 for studying any differences in mortality, clearance and persistence in mouse models.
The genomic analysis of the PA14 genome had identified pathogenicity islands PAPI-1 and PAPI-2, unique to PA14 and absent in the PAO1 genome (He et al., 2004
). The large set of extra virulence factors encoded by these pathogenicity islands may provide some virulence and/or persistence characteristics to the PA14 strain, which are absent in PAO1. Thus, strain PA14 and its pyomelanogenic mutant hmgA : : MAR2xT7 (Liberati et al., 2006
) were used to perform the mouse studies in this work.
Fig. 3
shows accumulated lung infection mortality on a daily basis for both the wild-type PA14 and PA14 hmgA : : MAR2xT7 mutant strains. Overall mouse mortality after 7 days of infection was similar for both strains, although the hmgA mutant tended to kill them at a slower pace. For instance, PA14 killed 94 % of the infected mice by the second day, whereas the hmgA mutant killed only 62 % (P=0.04). Likewise, PA14 hmgA : : MAR2xT7 showed reduced fitness in the acute respiratory infection model, since it was outcompeted by the wild-type PA14 strain after 48 h of co-infection (CI 0.38, P<0.001) (data not shown). This result shows that the inactivation of hmgA is associated with reduced virulence in the acute infection model.
|
|
To test the possible role of hmgA disruption on H2O2 resistance, we estimated the viability of cultures of strains PA14, PA14 hmgA : : MAR2xT7 and the complemented mutant PA14 hmgA : : MAR2xT7(pBBR1-HmgA) subjected to H2O2 treatment (25 and 50 mM). Fig. 5(A)
shows that hmgA disruption protects significantly against the effect of 50 mM peroxide after a 30, 45 or 60 min exposure. All three strains showed similar viability after exposure to 25 mM peroxide (data not shown).
|
In conclusion, the results of this section indicate that inactivation of the hmgA gene provides protection against H2O2 but not antibiotics.
Pyomelanin-containing supernatant is able to protect wild-type cells from H2O2
To gain an insight into whether the production of the pyomelanin pigment is responsible for H2O2 protection, wild-type non-producer PA14 cells, obtained from 48 h cultures in LB, were washed and resuspended in filter-sterilized supernatant from the PA14 hmgA : : MAR2xT7 pyomelanogenic mutant or, as control, its own supernatant (wild-type PA14), taken from cultures grown for 48 h in LB broth. Viable-cell counts determined before and after treatment showed that the supernatant from the mutant culture was able to protect the wild-type cells from the effect of H2O2 (Fig. 5B
). This result suggests that the pyomelanin pigment may be the cause of such protection in P. aeruginosa. This interpretation is also supported by a previous report indicating that Burkholderia cepacia may derive protection against host-generated free-radicals via scavenging of these radicals by melanin (Zughaier et al., 1999
). Our data may also explain why naturally occurring hyperproducer strains do not always take over the whole lung population when they appear in chronically infected patients, as non-producer strains may act as cheaters, and take advantage of the protection provided by hyperproducers without the associated cost (A. Oliver, unpublished).
Finally, as expected, the supernatant of the hyperproducer mutant did not provide protection against the four antibiotics tested (ceftazidime, imipenem, ciprofloxacin and tobramycin) (data not shown).
The results presented in this section show that pyomelanin hyperproduction in P. aeruginosa, caused by the disruption of hmgA, confers increased resistance to H2O2. The protection against reactive oxygen species (ROS) is an especially important feature for P. aeruginosa, as neutrophil levels are about 1500-fold higher in the infected CF lung than in uninfected individuals (Konstan et al., 1994
). Macrophages and monocytes produce superoxide anions in response to engulfed bacteria or bacterial products. These ROS help to kill phagocytosed bacteria, and since the production of ROS is a fundamental mechanism of the immune system to control infection, ROS sensitivity is one of the main handicaps for bacterial proliferation (Fazal, 1997
; Johansen et al., 1994
). The higher in vitro resistance to oxidative stress shown in vitro by the wild-type strain when protected by the supernatant from the hmgA mutant suggests that the advantage observed in vivo may be due to the hyperproduction of the pyomelanin pigment.
Concluding remarks
In conclusion, the results presented in this study demonstrate that: (i) inactivation of the hmgA gene in P. aeruginosa leads to the hyperproduction of pyomelanin; (ii) pyomelanogenic strains isolated from CF patients seem to lack HmgA activity, as complementation with the hmgA wild-type gene reverts the phenotype; (iii) an hmgA mutant strain is less virulent yet more persistent than the wild-type in lung infection models; and (iv) hmgA mutants show increased resistance to peroxide, probably due to the protective effect of the pyomelanin pigment itself.
Despite our in vitro results with peroxide suggesting that production of pyomelanin may be the cause of increased adaptation to chronicity, whether this production is the final cause of this increased adaptation or simply a side effect of hmgA inactivation is a topic to be studied in future.
The inactivation of hmgA can now be included among the adaptive mutations for chronic lung infection already described in natural isolates, such as hyperproduction of alginate, reduced growth rate, increased biofilm formation capacity, reduced expression of exoenzymes and increased antibiotic resistance.
| ACKNOWLEDGEMENTS |
|---|
Edited by: W. Bitter
| REFERENCES |
|---|
|
|
|---|
Bodey, G. P., Bolivar, R., Fainstein, V. & Jadeja, L. (1983). Infections caused by Pseudomonas aeruginosa. Rev Infect Dis 5, 279–313.[Medline]
Choi, J. Y., Sifri, C. D., Goumnerov, B. C., Rahme, L. G., Ausubel, F. M. & Calderwood, S. B. (2002). Identification of virulence genes in a pathogenic strain of Pseudomonas aeruginosa by representational difference analysis. J Bacteriol 184, 952–961.
Coon, S. L., Kotob, S., Jarvis, B. B., Wang, S., Fuqua, W. C. & Weiner, R. M. (1994). Homogentisic acid is the product of MelA, which mediates melanogenesis in the marine bacterium Shewanella colwelliana D. Appl Environ Microbiol 60, 3006–3010.
Doring, G., Holder, I. A. & Botzenhardt, K. (editors) (1987). Basic Research and Clinical Aspects of Pseudomonas aeruginosa. International Symposium, Tübingen, Germany, 1986. Basel: Karger.
Driffield, K., Miller, K., Bostock, J. M., O'Neill, A. J. & Chopra, I. (2008). Increased mutability of Pseudomonas aeruginosa in biofilms. J Antimicrob Chemother 61, 1053–1056.
Ernst, R. K., D'Argenio, D. A., Ichikawa, J. K., Bangera, M. G., Selgrade, S., Burns, J. L., Hiatt, P., McCoy, K., Brittnacher, M., Kas, A. & other authors (2003). Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis. Environ Microbiol 5, 1341–1349.[CrossRef][Medline]
Fazal, N. (1997). The role of reactive oxygen species (ROS) in the effector mechanisms of human antimycobacterial immunity. Biochem Mol Biol Int 43, 399–408.[Medline]
Fick, R. B., Jr (1993). Pathogenesis and disease. In Pseudomonas aeruginosa: the Opportunist. Boca Raton, FL: CRC.
Gilligan, P. H. (1991). Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 4, 35–51.
Govan, J. R. & Deretic, V. (1996). Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60, 539–574.
Haussler, S., Ziegler, I., Lottel, A., von Gotz, F., Rohde, M., Wehmhohner, D., Saravanamuthu, S., Tummler, B. & Steinmetz, I. (2003). Highly adherent small-colony variants of Pseudomonas aeruginosa in cystic fibrosis lung infection. J Med Microbiol 52, 295–301.
He, J., Baldini, R. L., Deziel, E., Saucier, M., Zhang, Q., Liberati, N. T., Lee, D., Urbach, J., Goodman, H. M. & Rahme, L. G. (2004). The broad host range pathogen Pseudomonas aeruginosa strain PA14 carries two pathogenicity islands harboring plant and animal virulence genes. Proc Natl Acad Sci U S A 101, 2530–2535.
Hoti, S. L. & Balaraman, K. (1993). Formation of melanin pigment by a mutant of Bacillus thuringiensis H-14. J Gen Microbiol 139, 2365–2369.
Hullo, M. F., Moszer, I., Danchin, A. & Martin-Verstraete, I. (2001). CotA of Bacillus subtilis is a copper-dependent laccase. J Bacteriol 183, 5426–5430.
Ivins, B. E. & Holmes, R. K. (1980). Isolation and characterization of melanin-producing (mel) mutants of Vibrio cholerae. Infect Immun 27, 721–729.
Ivins, B. E. & Holmes, R. K. (1981). Factors affecting phaeomelanin production by a melanin-producing (mel) mutant of Vibrio cholerae. Infect Immun 34, 895–899.
Jacobs, M. A., Alwood, A., Thaipisuttikul, I., Spencer, D., Haugen, E., Ernst, S., Will, O., Kaul, R., Raymond, C. & other authors (2003). Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 100, 14339–14344.
Johansen, H. K., Espersen, F., Cryz, S. J., Jr, Hougen, H. P., Fomsgaard, A., Rygaard, J. & Hoiby, N. (1994). Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection. Infect Immun 62, 3146–3155.
Konstan, M. W., Hilliard, K. A., Norvell, T. M. & Berger, M. (1994). Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 150, 448–454.[Abstract]
Kotob, S. I., Coon, S. L., Quintero, E. J. & Weiner, R. M. (1995). Homogentisic acid is the primary precursor of melanin synthesis in Vibrio cholerae, a Hyphomonas strain, and Shewanella colwelliana. Appl Environ Microbiol 61, 1620–1622.[Abstract]
Kovach, M. E., Elzer, P. H., Hill, D. S., Robertson, G. T., Farris, M. A., Roop, R. M., II & Peterson, K. M. (1995). Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. Gene 166, 175–176.[CrossRef][Medline]
Liberati, N. T., Urbach, J. M., Miyata, S., Lee, D. G., Drenkard, E., Wu, G., Villanueva, J., Wei, T. & Ausubel, F. M. (2006). An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants. Proc Natl Acad Sci U S A 103, 2833–2838.
Macia, M. D., Borrell, N., Segura, M., Gomez, C., Perez, J. L. & Oliver, A. (2006). Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob Agents Chemother 50, 975–983.
Mena, A., Macia, M. D., Borrell, N., Moya, B., de Francisco, T., Perez, J. L. & Oliver, A. (2007). Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice. J Bacteriol 189, 3665–3668.
Morrison, A. J., Jr & Wenzel, R. P. (1984). Epidemiology of infections due to Pseudomonas aeruginosa. Rev Infect Dis 6 (Suppl. 3), S627–S642.[Medline]
Mulcahy, H., O'Callaghan, J., O'Grady, E. P., Maciá, M. D., Borrell, N., Gómez, C., Casey, P. G., Hill, C., Adams, C. & other authors (2008). Pseudomonas aeruginosa RsmA plays an important role during murine infection by influencing colonization, virulence, persistence, and pulmonary inflammation. Infect Immun 76, 632–638.
Nosanchuk, J. D. & Casadevall, A. (2003). The contribution of melanin to microbial pathogenesis. Cell Microbiol 5, 203–223.[CrossRef][Medline]
Nosanchuk, J. D. & Casadevall, A. (2006). Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother 50, 3519–3528.
Oliver, A., Canton, R., Campo, P., Baquero, F. & Blazquez, J. (2000). High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288, 1251–1254.
Pritt, B., O'Brien, L. & Winn, W. (2007). Mucoid Pseudomonas in cystic fibrosis. Am J Clin Pathol 128, 32–34.
Ruzafa, C., Sanchez-Amat, A. & Solano, F. (1995). Characterization of the melanogenic system in Vibrio cholerae, ATCC 14035. Pigment Cell Res 8, 147–152.[CrossRef][Medline]
Salgado, A. & Blazquez, J. (2006). Determination of the structure of a hybrid between 2-(1,4-benzoquinone)acetic acid and a linear peptide by electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 20, 512–516.[CrossRef][Medline]
Sambrook, J. & Russell, D. W. (2001). Molecular Cloning: a Laboratory Manual, 3rd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
Smith, E. E., Buckley, D. G., Wu, Z., Saenphimmachak, C., Hoffman, L. R., D'Argenio, D. A., Miller, S. I., Ramsey, B. W., Speert, D. P. & other authors (2006). Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 103, 8487–8492.
Stover, C. K., Pham, X. Q., Erwin, A. L., Mizoguchi, S. D., Warrener, P., Hickey, M. J., Brinkman, F. S., Hufnagle, W. O., Kowalik, D. J. & other authors (2000). Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406, 959–964.[CrossRef][Medline]
Yabuuchi, E. & Ohyama, A. (1972). Characterization of pyomelanin producing strains of Pseudomonas aeruginosa. Int J Syst Bacteriol 22, 53–64.
Zhang, C., Huang, M. & Holloway, B. W. (1993). Mapping of the ben, ant and cat genes of Pseudomonas aeruginosa and evolutionary relationship of the ben region of P. aeruginosa and P. putida. FEMS Microbiol Lett 108, 303–309.[CrossRef][Medline]
Zughaier, S. M., Ryley, H. C. & Jackson, S. K. (1999). A melanin pigment purified from an epidemic strain of Burkholderia cepacia attenuates monocyte respiratory burst activity by scavenging superoxide anion. Infect Immun 67, 908–913.
Received 29 September 2008;
revised 15 December 2008;
accepted 23 December 2008.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |